AbbVie Submits Regulatory Applications to the US FDA and EMA for Skyrizi (risankizumab) to Treat Psoriatic Arthritis

 AbbVie Submits Regulatory Applications to the US FDA and EMA for Skyrizi (risankizumab) to Treat Psoriatic Arthritis

AbbVie Submits Regulatory Applications to the US FDA and EMA for Skyrizi (risankizumab) to Treat Psoriatic Arthritis

Shots:

  • The submission is based on two P-III studies KEEPsAKE-1 & -2 studies involves assessing Skyrizi (150mg) vs PBO in adult patients with active PsA who had an inadequate response or intolerant to biologic therapy and/or non-biologic DMARDs respectively
  • The 1EP and 2EP of both studies showed ACR20 response @24wks., improvements in disease activity, skin clearance, 90% improvement in PASI 90 & physical function as measured by HAQ-DI
  • The safety profile was generally consistent with the known profile of Skyriz in psoriasis patients, with no new safety risks observed. Skyrizi is an IL-23 inhibitor, being developed in collaboration with Boehringer Ingelheim

Click here to­ read full press release/ article | Ref: Abbvie | Image: The Street

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post